Depositing drug on the olfactory region of the nasal cavity is difficult to accomplish due to the complex architecture of the nasal cavity and the turbinate guided air path for inhaled breath through the nose. These natural structures act to prevent materials from depositing on the olfactory region as a way to protect this entry way into the central nervous system (CNS). Nasal drop or spray devices, such as the Pfieffer nasal spray devices (Radolfzell, Germany), are designed to saturate the lower nasal cavity. Drug deposited on the lower nasal cavity is absorbed into the blood stream instead of the CNS, eliminating an advantage of using the nasal route for CNS delivery.
A more elegant approach to the intranasal delivery of compounds or mixtures is needed.
Shown and described is one implementation of a device for the intranasal delivery of a compound including a y-junction having a base, a first branch of the y-junction radiating from the base, a second branch of the y-junction radiating from the base, a third branch of the y-junction radiating from the base, and an internal dose loading channel of the y-junction, a metered dose pump in fluid communication with the first branch of the y-junction, a conical spring associated with the second branch of the y-junction, a dose chamber in fluid communication with the third branch of the y-junction, a nozzle associated with the dose chamber, a diffuser compression fit between the internal dose loading channel and the dose chamber, an actuator grip surrounding the y-junction, and a housing, the y-junction residing within the housing.
In one aspect, the in-line nasal delivery device further includes a propellant canister in fluid communication with the second branch of the y-junction and held by the actuator grip, the conical spring between the propellant canister and the second branch of the y-junction.
In another aspect, the in-line nasal delivery device further includes a vial in fluid communication with the metered dose pump.
In yet another aspect, the in-line nasal delivery device further includes a pump fitment securing the metered dose pump to the vial.
In another implementation, shown and described is an in-line nasal delivery device for the intranasal delivery of a compound including a housing, the housing including a tip, an actuator, and a dose chamber, the tip and the dose chamber in fluid communication within the housing, a nozzle at a distal portion of the tip, the nozzle providing an outlet for the compound, and a pump in fluid communication with the dose chamber, the pump to move the compound into the dose chamber.
In one aspect, the in-line nasal delivery device further includes a propellant canister in communication with the housing, the propellant canister having a propellant valve and in fluid communication with the dose chamber.
In another aspect, the in-line nasal delivery device further includes a vial of compound cooperative with the pump to move the compound into the dose chamber.
In another aspect, the in-line nasal delivery device when actuated compresses the pump moving the compound into the dose chamber and actuation of the propellant valve disperses the propellant pushing the compound providing for the compound to exit the device through the nozzle openings.
The invention will best be understood by reference to the following detailed description of various implementations, taken in conjunction with any accompanying drawings. The discussion below is descriptive, illustrative and exemplary and is not to be taken as limiting the scope defined by any appended claims.
The foregoing aspects and many of the advantages will be more readily appreciated as the same become better understood by reference to the following detailed description, when taken in conjunction with the accompanying drawings, wherein:
When trade names are used herein, applicants intend to independently include the trade name product and formulation, the generic compound, and the active pharmaceutical ingredient(s) of the trade name product.
For clarity of disclosure, and not by way of limitation, the detailed description is divided into the subsections which follow.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art pertinent to the methods, apparatus and compositions described. As used herein, the following terms and phrases have the meanings ascribed to them unless specified otherwise:
“A” or “an” may mean one or more.
In one implementation, the in-line nasal delivery device 1 delivers compound into the nasal cavity and deposits compound in the nasal cavity beyond the nasal valve. The deposition includes the turbinates and/or the olfactory region. The compound delivered is a liquid. The compound may be a drug, active pharmaceutical ingredient, or a pharmaceutical formulation. The compound delivered may be a dose.
As shown in
In one aspect, the diffuser 20 is a frit. The diffuser provides for the conversion of the liquefied propellant in the propellant canister 5 to gas and/or an increase in temperature of the propellant.
In one aspect, the propellant valve 15 is a metered dose propellant valve.
In one aspect, the compound is supplied in the form of a sealed vial 30, e.g., of glass, that contains a quantity of liquid. In one aspect, the vial 30 has a neck that is sealed by a removable closure (not shown), for example but not limited to sealed with a plastic cover, crimped metal seal, and rubber stopper (for stability and sterility purposes). In one aspect, the vial 30 may contain the active pharmaceutical ingredient. When the closure is removed, the device 1 is engaged with the vial 30, in one aspect, by cooperation with the neck of the vial 30. A pump 25 moves the compound into the dose chamber 45.
The propellant canister 5 is a canister of a compressed gas or a liquefied propellant. Compressed gases include but are not limited to compressed air and compressed hydrocarbons. In one aspect, nitrogen or carbon dioxide. Liquefied propellants include but are not limited to chlorofluorocarbons and hydrofluoroalkanes. The canister 5 will generally be provided with a propellant valve 15 by which the gas flow can be controlled.
The tip 35 includes a nozzle 40. In one aspect, the nozzle 40 has a plurality of nozzle openings (not shown). Thru the plurality of nozzle openings, the compound and propellant is delivered to the nasal cavity.
Actuation of the propellant canister 5 is effectively coordinated with actuation of the pump 25 for the vial 30 for the compound. The arrangement may be such that actuation of the vial 30 for the compound causes actuation of the propellant canister 5.
As an example, the staging of the device 1 actuation is as follows. The housing 10 is compressed to prime the propellant canister 5. When the housing 10 is compressed, an actuator 50 remains stationary in the housing 10 while the propellant canister 5 and the vial 30 move towards the actuator 50. At this time, the propellant valve 15 associated with the propellant canister 5 is not actuated by compression. The actuator 50 acts upon the pump 25 compressing the pump 25 and the compound from the vial 30 is moved into the dose chamber 45. After a majority of the compound has moved into the dose chamber 45, the actuator 50 acts upon the propellant valve 15 and the propellant valve 15 begins to compress. The continued depression of the actuator 50 releases the propellant from the propellant canister 5. The propellant pushes the compound as it exits the device 1 through the nozzle openings 41 of the nozzle 40 located in the tip 35. The actuator 50 provides for first actuation of the pump 25, then once the pump 25 bottoms out, the continued depression of the actuator 50 provides for release of the propellant from the canister 5.
In an alternative implementation of the device 1 (not shown), the device 1 does not include a diffuser 20.
Initially, the vial 30 may be separate from the rest of the assembled device 100. At the time of use, the device 100 and vial 30 are taken out of their respective packaging. Prior to use, the vial 30 will generally be sealed. In the aspect where the vial 30 is covered by a plastic cover, metal seal and stopper, the plastic cover and metal seal are pulled away from the top of the vial 30, and the rubber stopper is removed from the vial 30. The vial 30 may be screwed into a pump fitment 180 located at the base of the device 100. For example, but not limited to, the vial 30 may have female threads which can be screwed into male threads on a pump fitment 180, or vice versa. The vial 30 may contain, for example but not limited to, inclusive of end points, 2-3 ml, in another aspect 2-2.5 ml of compound.
As shown in
As shown in
When oriented as to be used in operation, housed within the device's 100 housing 110, towards the top of the device 100, the propellant canister 140 press fits into a second branch of the y-junction 120, establishing the gas path through internal bores, through the diffuser 170 and to the dose chamber 150.
In this implementation of the device 100, the diffuser 170 is annular. As shown in
In one aspect, the diffuser 170 is a frit. The diffuser 170: (a) provides for the conversion of the liquefied propellant in the propellant canister 140 to gas; (b) provides an increase in temperature of the propellant; (c) acts to prevent the propellant from flowing back into the device 100; (d) acts to prevent the compound from flowing back into the device 100; and/or (e) acts to allows gas flow into the dose chamber 150 while preventing the compound from leaking out. The diffuser may be made of a porous polymer material.
The relationship in operation of the device 100 between the compound, the annular diffuser 170, the inner dose loading tube 230, the dose chamber 150 and the y-junction 120 are shown at least in
On the third leg of the y-junction 120 at a 45-degree angle, the dose chamber 150 press fits into the y-junction 120, completing the flow paths for both gas and fluid through the device. In one aspect, the angle is 30 degrees, 35 degrees, 40 degrees, 45 degrees, 50 degrees, 55 degrees, 60 degrees, inclusive of endpoints and intervening degrees.
The y-junction 120 may contain engagement ribs (not shown) to help secure and position the assembly within the housing 110 of the device 100.
The device 100 includes a pump fitment 180. The pump fitment 180 secures the metered dose pump 130 to the vial 30 and holds both components in place during device 100 use. One aspect of the pump fitment 180 is that it consists of engagement ribs that retain it within the housing 110, provide vertical displacement, and prevent rotation during installation of the vial 30.
The device 100 includes a dose chamber 150. The dose chamber 150 receives and stores the compound that has been pushed out of the inner tube of the y-junction 120. When the propellant canister 140 is actuated, the y-junction 120 and dose chamber 150 are pressurized and the propellant gas expels the compound out of the dose chamber 150. As shown in
The nozzle 190 is installed into the distal end (end opposite where the dose chamber 150 is press fit into the y-junction 120) of the dose chamber 150, forming a liquid and gas-tight seal around the outer diameter. During actuation of the device 100, propellant evacuates liquid compound from the dose chamber 150, pushing it out the nozzle 190.
The nozzle 190 forms the narrow plume angle (for example, an angle of 1 to 40 degrees, including endpoints and angles intermittent there between; in one aspect the angle is 5 degrees, 10 degrees, 15 degrees, 20 degrees, 25 degrees, 30 degrees, 35 degrees) multi-stream deposition. The nozzle 190 and resultant angle of the plume produced promotes delivery of the compound to the olfactory region of the user's nasal cavity.
In this implementation, as shown in
The housing 110 represents the body of the device 100. The housing 110 includes two different “clamshells” concealing the components of the device 100 and retaining all components to ensure functionality. The housing 110 houses the metered dose pump 130 and pump fitment 180, the actuator grip 210, the y-junction 120, the propellant canister 140, and the dose chamber 150. The nose cone 200 engages onto the outer geometry of the housing 110. The housing 110 is designed to assemble easily through the use of, for example but not limited to, mattel pins, snaps, post or screws, or a combination thereof, molded into the geometry.
The actuator grip 210 provides for actuation displacement by the user. The actuator grip 210 is composed of two parts, and surround the y-junction 120 and reside within the housing 110.
The metered dose pump 130 draws compound up from the vial 30 to the y-junction 120. The metered dose pump 130 may utilize a custom pump fitment 180 to promote functionality within the device 100, and allow attachment of the vial 30 via threads. The metered dose pump 130 may deliver, for example but not limited to, volumes, 180 μl, 200 μl, or 230 μl during actuation. Commercially available metered dose pumps 130 can be used.
For the device 100 to consistently deliver compound, the metered dose pump 130 must first deliver compound, followed by propellant canister 140 actuation to expel the compound. As shown in
The conical spring 220 is installed inline between the propellant canister 140 and y-junction 120. The actuator grip 210 physically holds the propellant canister 140. The user activates the device 100 by, for example, applying an in-line force acting down from the actuator grips 210, and up from the vial 30. This force simultaneously acts to activate both the metered dose pump 130 and the propellant canister 140. The conical spring 220 acts in parallel to the internal propellant canister spring, increasing the necessary force required to activate the propellant canister 140. By choosing the conical spring 220 such that the necessary force required to actuate the propellant canister 140 is in excess of the maximum necessary force required to completely actuate the metered dose pump 130, the device 100 provides that dose is loaded into the dose chamber 150 before propellant gas begins to expel compound from the device 100.
During device 100 actuation, the metered dose pump 130 draws liquid compound up from the vial 30 at the bottom of the device 100 via the y-junction 120, through the internal dose loading channel 230 and into the dose chamber 150. The internal dose loading channel 230 provides a clear route for the compound to be loaded ahead of the annular diffuser 170, without needed to physically pass through the porous material of the annular diffuser 170. As shown in
In the second stage of device 100 actuation, once the dose chamber 150 has been filled, the propellant canister 140 releases propellant which enters through the top of the y-junction 120, following the path shown by open arrow heads in
The propellant canister 140 provides the propulsive energy for the device 100. The stem of the propellant valve seats into the top receiver of the y-junction 120. During use, the user presses down on the actuator grips 210 which pulls the propellant canister 140 body down, actuating the propellant valve. This releases a metered volume of liquid propellant. As the propellant vaporizes and expands, the compound is forced out of the dose chamber 150 and out through the nozzle 190.
As an example of propellant, but not limited to, the propellant canister 140 uses HFA 134A as the propellant for the system. Other propellants are envisioned. There are commercially available propellant canisters 140.
The device 100, the propellant canister 140, and the vial 30 may all be included or provided together in a kit.
The following table provides data on one implementation of the device described herein.
The following clauses described multiple possible embodiments for implementing the features described in this disclosure. The various embodiments described herein are not limiting nor is every feature from any given embodiment required to be present in another embodiment. Any two or more of the embodiments may be combined together unless context clearly indicates otherwise. As used herein in this document “or” means and/or. For example, “A or B” means A without B, B without A, or A and B. As used herein, “comprising” means including all listed features and potentially including addition of other features that are not listed. “Consisting essentially of” means including the listed features and those additional features that do not materially affect the basic and novel characteristics of the listed features. “Consisting of” means only the listed features to the exclusion of any feature not listed.
Clause 1. A device for the intranasal delivery of a compound comprising:
a y-junction including a base, a first branch of the y-junction radiating from the base, a second branch of the y-junction radiating from the base, a third branch of the y-junction radiating from the base, and an internal dose loading channel of the y-junction;
a metered dose pump in fluid communication with the first branch of the y-junction;
a conical spring associated with the second branch of the y-junction;
a dose chamber in fluid communication with the third branch of the y-j unction;
a nozzle associated with the dose chamber;
a diffuser between the internal dose loading channel and the dose chamber;
an actuator grip surrounding the y-junction; and
a housing, the y-junction residing within the housing.
Clause 2. The device of any of clauses 1-11, further comprising:
a propellant canister in fluid communication with the second branch of the y-junction and held by the actuator grip, the conical spring between the propellant canister and the second branch of the y-junction.
Clause 3. The device of any of clauses 1-11, further comprising a vial in fluid communication with the metered dose pump.
Clause 4. The device of clause 3, further comprising a pump fitment securing the metered dose pump to the vial.
Clause 5. The device of any of clauses 1-11, further including a check-valve associated between the metered dose pump and the y-junction.
Clause 6. The device of any of clauses 1-11, further including a nose cone in engagement with the housing.
Clause 7. The device of clause 6 further comprising a dose cap covering the nose cone.
Clause 8. The device of any of clauses 1-11, wherein the third branch of the y-junction is at a 45-degree angle from the base of the y-junction.
Clause 9. The device of any of clauses 1-11, wherein the diffuser is annular.
Clause 10. The device of any of clauses 1-11, wherein the diffuser is a porous material.
Clause 11. The device of any of clauses 1-11, wherein the diffuser forms the bottom of the dose chamber.
Clause 12. A device for the intranasal delivery of a compound, the device comprising:
a housing, the housing including a tip, an actuator, and a dose chamber, the tip and the dose chamber in fluid communication within the housing;
a nozzle at a distal portion of the tip, the nozzle providing an outlet for the compound, the nozzle including a plurality of nozzle openings; and
a pump in fluid communication with the dose chamber, the pump to move the compound into the dose chamber upon actuation of the actuator.
Clause 13. The device of any of clauses 12-15, further comprising a propellant canister associated with the housing, the propellant canister having a propellant valve for actuation by the actuator, the propellant canister in fluid communication with the dose chamber.
Clause 14. The device of clauses 12-15, further comprising a vial of compound associated with the pump to move the compound into the dose chamber from the vial.
Clause 15. The device of clauses 12-15, further including a diffuser.
Clause 16. A device for the intranasal delivery of a compound to the olfactory region of the nasal cavity, the device comprising:
a housing, the housing including a tip, an actuator, and a dose chamber, the tip and the dose chamber in fluid communication with the housing;
a nozzle at a distal portion of the tip, the nozzle providing an outlet for the compound, the nozzle including a plurality of nozzle openings;
a pump in fluid communication with the dose chamber, the pump to move the compound into the dose chamber upon actuation of the actuator;
a propellant canister associated with the housing, the propellant canister having a propellant valve for actuation by the actuator, the propellant canister in fluid communication with the dose chamber; and
a vial of compound associated with the pump to move the compound into the dose chamber from the vial wherein the actuator upon actuation of the device compresses the pump moving the compound into the dose chamber and actuation of the propellant valve disperses the propellant pushing the compound providing for the compound to exit the device through the plurality of nozzle openings.
Clause 17. A kit including the device any of clauses 1-16, a propellant canister and a vial.
The present invention is not to be limited in scope by the specific implementations described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.
This application claims priority to U.S. Provisional Patent Application No. 62/216,789 filed Sep. 10, 2015, the contents of which are hereby incorporated by reference herein in their entirety.
Filing Document | Filing Date | Country | Kind |
---|---|---|---|
PCT/US2016/051169 | 9/9/2016 | WO | 00 |
Publishing Document | Publishing Date | Country | Kind |
---|---|---|---|
WO2017/044897 | 3/16/2017 | WO | A |
Number | Name | Date | Kind |
---|---|---|---|
2933259 | Raskin | Apr 1960 | A |
3157179 | Paullus et al. | Nov 1964 | A |
3425414 | Roche | Feb 1969 | A |
3704812 | Marand | Dec 1972 | A |
3741443 | Marand | Jun 1973 | A |
3888253 | Watt et al. | Jun 1975 | A |
3906950 | Cocozza | Sep 1975 | A |
3908654 | Lhoest et al. | Sep 1975 | A |
3921857 | Riccio | Nov 1975 | A |
3971377 | Damani | Jul 1976 | A |
3982668 | Riccio | Sep 1976 | A |
4095596 | Grayson | Jun 1978 | A |
4187985 | Goth | Feb 1980 | A |
4227522 | Carris | Oct 1980 | A |
4353365 | Hallworth et al. | Oct 1982 | A |
4412573 | Zdeb | Nov 1983 | A |
4462983 | Azria et al. | Jul 1984 | A |
4620670 | Hughes | Nov 1986 | A |
4702415 | Hughes | Oct 1987 | A |
4896832 | Howlett | Jan 1990 | A |
4995385 | Valentini et al. | Feb 1991 | A |
5224471 | Marelli et al. | Jul 1993 | A |
5307953 | Regan | May 1994 | A |
5331954 | Rex et al. | Jul 1994 | A |
5349947 | Newhouse et al. | Sep 1994 | A |
5382236 | Otto et al. | Jan 1995 | A |
5398850 | Sancoff et al. | Mar 1995 | A |
5435282 | Haber et al. | Jul 1995 | A |
5505193 | Ballini et al. | Apr 1996 | A |
5516006 | Meshberg | May 1996 | A |
5711488 | Lund | Jan 1998 | A |
5715811 | Ohki et al. | Feb 1998 | A |
5756483 | Merkus | May 1998 | A |
5797390 | McSoley | Aug 1998 | A |
5814020 | Gross | Sep 1998 | A |
5819730 | Stone et al. | Oct 1998 | A |
5823183 | Casper et al. | Oct 1998 | A |
5881719 | Gottenauer et al. | Mar 1999 | A |
5901703 | Ohki et al. | May 1999 | A |
5906198 | Flickinger | May 1999 | A |
5910301 | Farr et al. | Jun 1999 | A |
5942251 | Merkus | Aug 1999 | A |
5954696 | Ryan | Sep 1999 | A |
6062213 | Fuisz et al. | May 2000 | A |
6092522 | Calvert et al. | Jul 2000 | A |
6145703 | Opperman | Nov 2000 | A |
6158676 | Hughes | Dec 2000 | A |
6180603 | Frey | Jan 2001 | B1 |
6186141 | Pike et al. | Feb 2001 | B1 |
6189739 | von Schuckmann | Feb 2001 | B1 |
6294153 | Modi | Sep 2001 | B1 |
6302101 | Py | Oct 2001 | B1 |
6313093 | Frey | Nov 2001 | B1 |
6347789 | Rock | Feb 2002 | B1 |
6367471 | Genosar et al. | Apr 2002 | B1 |
6367473 | Käfer | Apr 2002 | B1 |
6382465 | Greiner Perth | May 2002 | B1 |
6410046 | Lerner | Jun 2002 | B1 |
6491940 | Levin | Dec 2002 | B1 |
6540983 | Adjei et al. | Apr 2003 | B1 |
6569463 | Patel et al. | May 2003 | B2 |
6585172 | Arghyris | Jul 2003 | B2 |
6585957 | Adjei et al. | Jul 2003 | B1 |
6585958 | Keller et al. | Jul 2003 | B1 |
6595202 | Gañán Calvo | Jul 2003 | B2 |
6622721 | Vedrine et al. | Sep 2003 | B2 |
6644305 | MacRae et al. | Nov 2003 | B2 |
6644309 | Casper et al. | Nov 2003 | B2 |
6647980 | Gizurarson | Nov 2003 | B1 |
6681767 | Patton et al. | Jan 2004 | B1 |
6684879 | Coffee et al. | Feb 2004 | B1 |
6701916 | Mezzoli | Mar 2004 | B2 |
6715485 | Djupesland | Apr 2004 | B1 |
6734162 | Van Antwerp et al. | May 2004 | B2 |
6810872 | Ohki et al. | Nov 2004 | B1 |
6923988 | Patel et al. | Aug 2005 | B2 |
7033598 | Lerner | Apr 2006 | B2 |
7051734 | Casper et al. | May 2006 | B2 |
7163013 | Harrison | Jan 2007 | B2 |
7182277 | Vedrine et al. | Feb 2007 | B2 |
7200432 | Lerner et al. | Apr 2007 | B2 |
7214209 | Mazzoni | May 2007 | B2 |
7231919 | Giroux | Jun 2007 | B2 |
7258119 | Mazzoni | Aug 2007 | B2 |
7296566 | Alchas | Nov 2007 | B2 |
7347201 | Djupesland | Mar 2008 | B2 |
7377901 | Djupesland et al. | May 2008 | B2 |
7476689 | Santus et al. | Jan 2009 | B2 |
7481218 | Djupesland | Jan 2009 | B2 |
7543581 | Djupesland | Jun 2009 | B2 |
7597216 | Behar | Oct 2009 | B2 |
7655619 | During et al. | Feb 2010 | B2 |
7740014 | Djupesland | Jun 2010 | B2 |
7784460 | Djupesland et al. | Aug 2010 | B2 |
7799337 | Levin | Sep 2010 | B2 |
7832394 | Schechter et al. | Nov 2010 | B2 |
7841337 | Djupesland | Nov 2010 | B2 |
7841338 | Dunne et al. | Nov 2010 | B2 |
7854227 | Djupesland | Dec 2010 | B2 |
7866316 | Giroux | Jan 2011 | B2 |
7905229 | Giroux et al. | Mar 2011 | B2 |
7934503 | Djupesland et al. | May 2011 | B2 |
7975690 | Djupesland | Jul 2011 | B2 |
7994197 | Cook et al. | Aug 2011 | B2 |
8001963 | Giroux | Aug 2011 | B2 |
8047202 | Djupesland | Nov 2011 | B2 |
8119639 | Cook et al. | Feb 2012 | B2 |
8122881 | Giroux | Feb 2012 | B2 |
8146589 | Djupesland | Apr 2012 | B2 |
8148377 | Cook et al. | Apr 2012 | B2 |
8171929 | Djupesland et al. | May 2012 | B2 |
8327844 | Djupesland | Dec 2012 | B2 |
8408427 | Wong | Apr 2013 | B2 |
8448637 | Giroux | May 2013 | B2 |
8511303 | Djupesland | Aug 2013 | B2 |
8517026 | Amon | Aug 2013 | B2 |
8522778 | Djupesland | Sep 2013 | B2 |
8550073 | Djupesland | Oct 2013 | B2 |
8555877 | Djupesland | Oct 2013 | B2 |
8555878 | Djupesland | Oct 2013 | B2 |
8596278 | Djupesland | Dec 2013 | B2 |
8733342 | Giroux et al. | May 2014 | B2 |
8757146 | Hoekman et al. | Jun 2014 | B2 |
8800555 | Djupesland | Aug 2014 | B2 |
8839790 | Beck Arnon | Sep 2014 | B2 |
8875794 | Carlsen et al. | Nov 2014 | B2 |
8899229 | Djupesland et al. | Dec 2014 | B2 |
8899230 | Immel | Dec 2014 | B2 |
8910629 | Djupesland et al. | Dec 2014 | B2 |
8925544 | Flickinger | Jan 2015 | B2 |
8978647 | Djupesland et al. | Mar 2015 | B2 |
8987199 | Abdel Maksoud et al. | Mar 2015 | B2 |
9010325 | Djupesland et al. | Apr 2015 | B2 |
9038630 | Djupesland et al. | May 2015 | B2 |
9067034 | Djupesland et al. | Jun 2015 | B2 |
9072857 | Djupesland | Jul 2015 | B2 |
9101539 | Nagata et al. | Aug 2015 | B2 |
9119932 | Djupesland | Sep 2015 | B2 |
9180264 | Young et al. | Nov 2015 | B2 |
9272104 | Djupesland | Mar 2016 | B2 |
9446207 | Jung | Sep 2016 | B2 |
9550036 | Hoekman | Jan 2017 | B2 |
9649456 | Djupesland et al. | May 2017 | B2 |
9833451 | Cook et al. | Dec 2017 | B2 |
20020017294 | Py | Feb 2002 | A1 |
20020054856 | Jones | May 2002 | A1 |
20020092520 | Casper et al. | Jul 2002 | A1 |
20030017119 | Rabinowitz et al. | Jan 2003 | A1 |
20030091513 | Mohsen et al. | May 2003 | A1 |
20030114476 | Plachetka et al. | Jun 2003 | A1 |
20030158527 | Mezzoli | Aug 2003 | A1 |
20030198669 | Cutler et al. | Oct 2003 | A1 |
20030217748 | Giroux | Nov 2003 | A1 |
20040068222 | Brian | Apr 2004 | A1 |
20040238574 | Merk et al. | Dec 2004 | A1 |
20050023376 | Anderson | Feb 2005 | A1 |
20050028812 | Djupesland | Feb 2005 | A1 |
20050036985 | Ensoli | Feb 2005 | A1 |
20050098172 | Anderson | May 2005 | A1 |
20050142072 | Birch et al. | Jun 2005 | A1 |
20050274378 | Bonney et al. | Dec 2005 | A1 |
20060107957 | Djupesland | May 2006 | A1 |
20060147389 | Staniforth et al. | Jul 2006 | A1 |
20060219813 | Morrison | Oct 2006 | A1 |
20060240092 | Breitenkamp et al. | Oct 2006 | A1 |
20060246070 | Heavner et al. | Nov 2006 | A1 |
20070056585 | Davies et al. | Mar 2007 | A1 |
20070068514 | Giroux | Mar 2007 | A1 |
20070074722 | Giroux et al. | Apr 2007 | A1 |
20070119451 | Wang et al. | May 2007 | A1 |
20070131224 | Giroux | Jun 2007 | A1 |
20070172517 | Ben Sasson et al. | Jul 2007 | A1 |
20070202051 | Schuschnig | Aug 2007 | A1 |
20070253913 | Mohsen et al. | Nov 2007 | A1 |
20080017190 | Anandampillai et al. | Jan 2008 | A1 |
20080054099 | Giroux et al. | Mar 2008 | A1 |
20080163874 | Djupesland | Jul 2008 | A1 |
20080178871 | Genova et al. | Jul 2008 | A1 |
20080223363 | Djupesland | Sep 2008 | A1 |
20080305077 | Frey et al. | Dec 2008 | A1 |
20090216183 | Minotti | Aug 2009 | A1 |
20090320832 | Djupestand | Dec 2009 | A1 |
20100081663 | Cook et al. | Apr 2010 | A1 |
20100199984 | Williams, III et al. | Aug 2010 | A1 |
20100242958 | Jinks et al. | Sep 2010 | A1 |
20110045088 | Tsutsui | Feb 2011 | A1 |
20110053859 | Deadwyler et al. | Mar 2011 | A1 |
20120195959 | Ishii | Aug 2012 | A1 |
20130180524 | Shahaf et al. | Jul 2013 | A1 |
20130327323 | Rubin | Dec 2013 | A1 |
20140014104 | Hoekman | Jan 2014 | A1 |
20140034051 | Addington et al. | Feb 2014 | A1 |
20140083424 | Hoekman | Mar 2014 | A1 |
20140170220 | Cartt et al. | Jun 2014 | A1 |
20140343494 | Hoekman et al. | Nov 2014 | A1 |
20150057287 | Cook et al. | Feb 2015 | A1 |
20150216823 | Chatterjee | Aug 2015 | A1 |
20150258178 | Gong | Sep 2015 | A1 |
20160101245 | Hoekman et al. | Apr 2016 | A1 |
20160228433 | Haruta et al. | Aug 2016 | A1 |
20160367771 | Djupesland | Dec 2016 | A1 |
20170043109 | Hoekman et al. | Feb 2017 | A1 |
20170196861 | Cook et al. | Jul 2017 | A1 |
20180360110 | Marsot | Dec 2018 | A1 |
20190000753 | Narasimha Murthy et al. | Jan 2019 | A1 |
20190001088 | Petit | Jan 2019 | A1 |
20190209463 | Hoekman et al. | Jul 2019 | A1 |
20190275036 | Haruta et al. | Sep 2019 | A1 |
Number | Date | Country |
---|---|---|
1006872 | Jan 1995 | BE |
201759968 | Mar 2011 | CN |
202263268 | Jun 2012 | CN |
203139302 | Aug 2013 | CN |
19518580 | Nov 1996 | DE |
102013100473 | Jul 2014 | DE |
0689438 | Jan 1996 | EP |
0865789 | Jan 1999 | EP |
1165044 | Jan 2002 | EP |
1165044 | Jun 2004 | EP |
806284 | Dec 1958 | GB |
1493614 | Nov 1977 | GB |
1517642 | Jul 1978 | GB |
S 50-78912 | Jun 1975 | JP |
H08322934 | Dec 1996 | JP |
2014-530637 | Nov 2014 | JP |
WO 1986001731 | Mar 1986 | WO |
WO 9422445 | Oct 1994 | WO |
WO 1999013930 | Mar 1999 | WO |
WO 2000054887 | Sep 2000 | WO |
WO 2001036033 | May 2001 | WO |
WO 2002009707 | Feb 2002 | WO |
WO 03106840 | Dec 2003 | WO |
WO-2005025506 | Mar 2006 | WO |
WO 2007012853 | Feb 2007 | WO |
WO 2007081948 | Jul 2007 | WO |
WO 2007081948 | Apr 2008 | WO |
WO 2008059385 | May 2008 | WO |
WO 2015044782 | Apr 2015 | WO |
WO 2017044897 | Mar 2017 | WO |
WO 2018025089 | Feb 2018 | WO |
WO 2019008439 | Jan 2019 | WO |
Entry |
---|
Alfonso R. Gennaro (Remington' s: the Science and Practice of Pharmacy, 1995, nineteenth Edition, vol. 1, p. 806) (Year: 1995). |
PCT International Search Report and Written Opinion, International Application No. PCT/US2016/051169, dated Jan. 26, 2017, 9 pp. |
PCT International Preliminary Report on Patentability for PCT International Application No. PCT/US2016/051169, dated Mar. 29, 2018, six pages. |
European Patent Office, Supplementary European Search Report, European Patent No. 16845229, dated Apr. 9, 2019, 8 pages. |
The Patent Office of the People's Republic of China, First Office Action, CN Patent Application No. 201680060459.8, dated Apr. 14, 2020, 22 pages. |
Japan Patent Office, Official Notice of Rejection, JP Patent Application No. 2018-513344, dated Apr. 7, 2020, nine pages. |
Appasaheb, et al., “Review on Intranasal Drug Delilvery System”, Journal of Advanced Pharmacy Education and Research, vol. 3, Issue 4, Oct. 2013, 14 pages. |
Aurora, S. K. et al., “A Randomized, Double Blind, Placebo-Controlled Study of MAP0004 in Adult Patients With Migraine,” Headache, Jun. 2009, pp. 826-837, vol. 49, No. 6. |
Australian New Zealand Clinical Trials Registry, “A Phase I, Comparative Bioavailability Study of Dihydroergotamine Mesylate (DHE) Administered by I123 Precision Olfactory Delivery (PODTM) Device Nasal Spray, DHE for Injection (Intravenous), and Migranal® Nasal Spray in Healthy Male and Female adult Subjects,” 2017, 7 pages. |
Baron, “Orally Inhaled Dihydroergotamine; Reviving and Improving a Classic”, Future Neurology, May 2011, 11 pages. |
Constantino, et al., “Intranasal administration of acetylcholinesterase inhibitors”, BMC Neuroscience, Dec. 10, 2008, 3 pages. |
Cook, R. O. et al., “Reduced Adverse Event Profile of Orally Inhaled DHE (MAP0004) vs IV DHE: Potential Mechanism,” Headache, Nov./Dec. 2009, pp. 1423-1434, vol. 49, No. 10. |
“D.H.E. 45 (dihydroergotamine mesylate) Injection, USP,” Valeant Pharmaceuticals North America, Aug. 2008, 16 pages. |
European Patent Office, EP Office Action for 14727320.5, dated Nov. 9, 2016, 6 pages. |
European Patent Office, EP Search Report for 09707800.0 dated Jul. 1, 2015, 12 pages. |
European Patent Office, EP Search Report for 11818832.5 dated Sep. 24, 2014, 6 pages. |
Hanson, et al., “Intranasal delivery of growth differentiation factor 5 to the central nervous system”, Drug Delivery, 19(3):149-54, Feb. 2012, 7 pages. |
Headache Classification Committee of the International Headache Society (IHS), “The International Classification of Headache Disorders, 3rd edition,” Cephalalgia, 2018, 211 pages, vol. 38, No. 1. |
Hoekman, J.D., “The Impact of Enhanced Olfactory Deposition and Retention on Direct Nose-to-Brain Drug Delivery”, UMI Dissertation Publishing, Apr. 11, 2011, 181 pages. |
Humbert, H. et al., “Human pharmacokinetics of dihydroergotamine administered by nasal spray,” Clinical Pharmacology & Therapeutics, Sep. 1996, p. 265-275, vol. 60, No. 3. |
Impel Neuropharma, “Migraine Treatment,” Apr. 29, 2016, three pages, [Online] [Retrieved on Jul. 19, 2017], Retrieved from the Internet <URL: http://web.archive.org/web/20160429165231/impelnp.com/migraine-treatment/>. |
Impel Neuropharma, “POD Technology,” Apr. 29, 2016, four pages, [Online] [Retrieved on Jul. 19, 2017], Retrieved from the Internet <URL: http://web.archive.org/web/20160429165242/http://impelnp.com:80/pod-technology/>. |
Intellectual Property India Patent Application No. IN 201741000065, filed Jul. 2, 2017, Applicant: Dr. Reddy's Laboratories Limited. |
Iwashima, F. et al., “STS101 (Dry Powder Intranasal Dihydroergotamine) Drug-Device Combination Achieves Consistent and Robust Delivery Performance for Migraine Patients,” International Headache Conference, Sep. 5-8, 2019, one page. |
Kellerman, D. J. et al., “Assessment of the Consistency of Absorption of Dihydroergotamine Following Oral Inhalation: Pooled results from Four Clinical Studies,” Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2013, pp. 297-306, vol. 26, No. 5. |
Kumar, et al., “Nasal Drug Delivery: A Potential Route for Brain Targeting” The Pharma Innovation Journal, vol. 2, No. 1, Mar. 2013, 9 pages. |
“Make the Most of MIGRANAL: Administration Instructions: How to Use MIGRANAL Nasal Spray,” MIGRANAL Nasal Spray, Valeant Pharmaceuticals International, Inc., 2016, 7 pages. |
Mauskop, A., “Getting medicine straight from the nose to the brain,” Headache NewsBlog, Jan. 6, 2013, two pages, [Online] [Retrieved on Jun. 23, 2017], Retrieved from the Internet <URL: https://www.nyheadache.com/blog/getting-medicine-straight-from-the-nose-to-the-brain/>. |
Mauskop, A., “Getting medicine straight from the nose to the brain,” New York Headache blog, Jan. 6, 2013, 2 pages, [Online], [Retrieved Jun. 23, 2017], Retrieved from the Internet: <URL:https://www.nyheadache.com/blog/getting-medicine-straight-from-the-nose-to-the-brain/>. |
“Migranal Product Label,” Valeant Pharmaceuticals North America LLC, Nov. 2014, six pages. |
NIH, “A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects,” U.S. National Library of Medicine, ClinicalTrials.gov, Mar. 14, 2019, seven pages, [Online] [Retrieved on Dec. 24, 2019], Retrieved from the Internet <URL: https://clinicaltrials.gov/ct2/show/NCT03874832>. |
NIH, “A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine (EMERGE),” U.S. National Library of Medicine, ClinicalTrials.gov, Apr. 3, 2019, seven pages, [Online] [Retrieved on Dec. 24, 2019], Retrieved from the Internet <URL: https://clinicaltrials.gov/ct2/show/NCT03901482>. |
Ozsoy, et al., “Nasal Delivery of High Molecular Weight Drugs”, Molecules Journal, Sep. 23, 2009, 26 pages. |
Parvathi, “Intranasal Drug Delivery to Brain: An Overview,” published in the International Journal of Research in Pharmacy and Chemistry 2012, 2(3), 7 pages. |
PCT International Search Report, PCT Application No. PCT/US/2009/033468 dated Dec. 2, 2009, 5 pages. |
PCT International Search Report, PCT Application No. PCT/IB2014/002706, dated Mar. 20, 2015, four pages. |
PCT Search Report and Written Opinion, PCT Application No. PCT/US2011/048435, dated Mar. 27, 2012, 14 pages. |
PCT Invitation to Pay Additional Fees and, where Applicable, Protest Fee, PCT Application No. PCT/US2019/012405, Mar. 4, 2019, two pages. |
Renner, et al., “Intranasal delivery of growth differentiation factor 5 to the central nervous system,” Drug Delivery, Feb. 2012, 7 pages. |
Saper, J. R. et al., “Pharmacology of Dihydroergotamine and Evidence for Efficacy and Safety in Migraine,” Headache, Nov. 2006, pp. S171-S181, vol. 46, No. S4. |
Shrewsbury, S. B. et al., “Intrapulmonary and intravenous administrations of dihydroergotamine mesylate have similar cardiovascular effects in the conscious dog,” British Journal of Pharmacology, Jul. 2008, pp. 1254-1265, vol. 154, No. 6. |
Shrewsbury, S. B. et al., “Randomized, double-blind, placebo-controlled study of the safety, tolerability and pharmacokinetics of MAP0004 (orally-inhaled DHE) in adult asthmatics,” Current Medical Research and Opinion, 2008, pp. 1977-1985, vol. 24, No. 7. |
Shrewsbury, S. B. et al., “Safety and Pharmacokinetics of Dihydroergotamine Mesylate Administered via a Novel (Tempo™) Inhaler,” Headache, Mar. 2008, pp. 355-367, vol. 48, No. 3. |
Shrewsbury, S. B. et al., STOP 101: A Phase 1, Randomized, Open-Label, Comparative Bioavailability Study of INP104, Dihydroergotamine Mesylate (DHE) Administered Intranasally by a 1123 Precision Olfactory Delivery (POD®) Device, in Healthy Adult Subjects, Headache, Mar. 2019, 16 pages, vol. 59, No. 3. |
Shrewsbury, S.B. et al., “Intrapulmonary and intravenous administrations of dihydroergotamine mesylate have similar cardiovascular effects in the conscious dog,” Nature Publishing Group, 2008, vol. 154, No. 6, 12 pages. |
Shrewsbury, S.B., et al., “Safety, Tolerability and Comparative Bioavailability of a Novel Intranasal DHE Product (INP104),” Impel Neuropharma, American Headache Society 60th Annual Meeting, 2018, 1 page. |
Silberstein, S.D. et al., “Dihydroergotamine: a review of formulation approaches for the acute treatment of migraine,” CNS Drugs, 2013, p. 385-394, vol. 27, No. 5. |
Silberstein, S. D. et al., “Dihydroergotamine (DHE)—Then and Now: A Narrative Review,” Headache, 2019, 18 pages. |
Silberstein, S.D., et al., “Ergotamine and dihydroergotamine: history, pharmacology, and efficacy,” Headache: The Journal of Head and Face Pain, 2003, vol. 43, No. 2, pp. 144-166. |
Stevens, et al., “Systemic and Direct Nose-to-Brain Transport Pharmacokinetic Model for Remoxipride after Intravenous and Intranasal Administration”, in “Drug Metabolism and Disposition”, The American Society for Pharmacology and Experimental Therapeutics, 2011, vol. 39, No. 12, 8 pages. |
Strom, S. et al., “Comparison of the Pharmacokinetics of STS101, an Intranasal Dry Power Formulation of Dihydroergotamine, with Other Intranasal, Injectable, and Oral Inhaled DHE Formulations,” International Headache Conference, Sep. 5-8, 2019, one page. |
Talegaonkar, et al., “Intranasal delivery: an approach to bypass the blook brain barrier”, Indian J Pharmacol, Jun. 2004, vol. 36, Issue 3, 8 pages. |
Van Der Kuy, P-H. M. et al., “Bioavailability of intranasal formulations of dihydroergotamine,” European Journal of Clinical Pharmacology, Nov. 1999, pp. 677-680, vol. 55, No. 9. |
Wang, Y. et al., Abstract of “Brain uptake of dihydroergotamine after intravenous and nasal administration in the rat,” Biopharm Drug Dispos., Dec. 1998, two pages, [Online] [Retrieved on Jul. 18, 2017], Retrieved from the Internet <URL: https://pubmed.ncbi.nlm.nih.gov/9872338/>. |
Westin et al, “Direct Nose to Brain Transfer of Morphine After Nasal Administration to Rats”, Pharmaceutical Research, vol. 23, No. 3, Mar. 2006, 8 pgs. |
Westin, “Olfactory Transfer of Analgesic Drugs After Nasal Administration”, Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Pharmacy 55, May 11, 2007, 66 pages. |
Yamada, et al., “Nose-to-brain delivery of TS-002, prostaglandin D2 analogue”, Journal of Drug Targeting, Jan. 2007, 9 pages. |
Yimam, et al., “Effects of lipid association on lomustine (CCNU) administered intracerebrally to syngeneic 36B-10 rat brain tumors”, Cancer Letters 244(2), Dec. 2006, 9 pages. |
Ying, “The nose may help the brain: intranasal drug delivery for treating neurological diseases” Future Medicine, 3(1), Jan. 2008, 4 pages. |
Zhang, et al, “The brain targeting efficiency following nasally applied MPEG-PLA nanoparticles in rats”, Journal of Drug Targeting, Jun. 2006, 11 pages. |
China National Intellectual Property Administration, Notice of Allowance, Chinese Patent Application No. 201680060459.8, dated May 8, 2021, three pages (with concise explanation of relevance). |
China National Intellectual Property Administration, Search Report, Chinese Patent Application No. 201680060459.8, dated Apr. 15, 2021, six pages. |
Djupesland, G., “Nasal drug delivery devices: characteristics and performance in a clinical perspective—a review,” Drug Delivery and Translational Research, 2013, pp. 42-62, vol. 3. |
Righton, L., “Nasal MDIs—moving beyond nasal allergy,” manufacturing chemist, Sep. 2014, pp. xi-xiii. |
Number | Date | Country | |
---|---|---|---|
20180256836 A1 | Sep 2018 | US |
Number | Date | Country | |
---|---|---|---|
62216789 | Sep 2015 | US |